Sign up Australia
Proactive Investors - Run By Investors For Investors

The Hydroponics Company makes key appointment following medical cannabis partnership

Debbie Ormsby will lead Canndeo to fast-track medicinal cannabis products into Australia.
The Hydroponics Company makes key appointment following medical cannabis partnership
THC shares have increased five-fold to over $1 since listing in May

The Hydroponics Company Ltd (ASX:THC) has appointed the experienced Debbie Ormsby as chief commercial officer. 

Ormsby brings significant pharmaceutical and biotech expertise with extensive experience in end to end product commercialisation within the pharmaceutical markets.

The appointment follows the company's wholly-owned subsidiary, Canndeo Limited, locking in off-shore supply of medicinal cannabis by entering into a partnership with BOL Pharma.

READ NOW: The Hydroponics Company in company making partnership with Israel's BOL Pharma

BOL Pharma is one of Israel’s leading medicinal cannabis producers.

View full THC profile View Profile

The Hydroponics Company Timeline

Related Articles

mri scanner
July 24 2017
The Assessa PML platform is designed to facilitate the remote transfer, management and storage of MRI scans to help doctors detect progressive multifocal leukoencephalopathy
Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Richard Lipscombe talked revenue generation and growth path with investors.
Paradigm Biopharmaceuticals: Access latest PPT from Proactive's CEO Sessions
May 19 2017
Paul Rennie talked timeline to clinical trial results with investors.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use